Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP) : a population-based test-negative case-control study
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: People with cancer are at increased risk of hospitalisation and death following infection with SARS-CoV-2. Therefore, we aimed to conduct one of the first evaluations of vaccine effectiveness against breakthrough SARS-CoV-2 infections in patients with cancer at a population level.
METHODS: In this population-based test-negative case-control study of the UK Coronavirus Cancer Evaluation Project (UKCCEP), we extracted data from the UKCCEP registry on all SARS-CoV-2 PCR test results (from the Second Generation Surveillance System), vaccination records (from the National Immunisation Management Service), patient demographics, and cancer records from England, UK, from Dec 8, 2020, to Oct 15, 2021. Adults (aged ≥18 years) with cancer in the UKCCEP registry were identified via Public Health England's Rapid Cancer Registration Dataset between Jan 1, 2018, and April 30, 2021, and comprised the cancer cohort. We constructed a control population cohort from adults with PCR tests in the UKCCEP registry who were not contained within the Rapid Cancer Registration Dataset. The coprimary endpoints were overall vaccine effectiveness against breakthrough infections after the second dose (positive PCR COVID-19 test) and vaccine effectiveness against breakthrough infections at 3-6 months after the second dose in the cancer cohort and control population.
FINDINGS: The cancer cohort comprised 377 194 individuals, of whom 42 882 had breakthrough SARS-CoV-2 infections. The control population consisted of 28 010 955 individuals, of whom 5 748 708 had SARS-CoV-2 breakthrough infections. Overall vaccine effectiveness was 69·8% (95% CI 69·8-69·9) in the control population and 65·5% (65·1-65·9) in the cancer cohort. Vaccine effectiveness at 3-6 months was lower in the cancer cohort (47·0%, 46·3-47·6) than in the control population (61·4%, 61·4-61·5).
INTERPRETATION: COVID-19 vaccination is effective for individuals with cancer, conferring varying levels of protection against breakthrough infections. However, vaccine effectiveness is lower in patients with cancer than in the general population. COVID-19 vaccination for patients with cancer should be used in conjunction with non-pharmacological strategies and community-based antiviral treatment programmes to reduce the risk that COVID-19 poses to patients with cancer.
FUNDING: University of Oxford, University of Southampton, University of Birmingham, Department of Health and Social Care, and Blood Cancer UK.
| Errataetall: |
CommentIn: Lancet Oncol. 2022 Jun;23(6):693-695. - PMID 35617990 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
The Lancet. Oncology - 23(2022), 6 vom: 26. Juni, Seite 748-757 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Lennard Y W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 06.06.2022 Date Revised 10.02.2024 published: Print-Electronic CommentIn: Lancet Oncol. 2022 Jun;23(6):693-695. - PMID 35617990 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1470-2045(22)00202-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341403245 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341403245 | ||
| 003 | DE-627 | ||
| 005 | 20240210232431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(22)00202-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM341403245 | ||
| 035 | |a (NLM)35617989 | ||
| 035 | |a (PII)S1470-2045(22)00202-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Lennard Y W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP) |b a population-based test-negative case-control study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.06.2022 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Lancet Oncol. 2022 Jun;23(6):693-695. - PMID 35617990 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: People with cancer are at increased risk of hospitalisation and death following infection with SARS-CoV-2. Therefore, we aimed to conduct one of the first evaluations of vaccine effectiveness against breakthrough SARS-CoV-2 infections in patients with cancer at a population level | ||
| 520 | |a METHODS: In this population-based test-negative case-control study of the UK Coronavirus Cancer Evaluation Project (UKCCEP), we extracted data from the UKCCEP registry on all SARS-CoV-2 PCR test results (from the Second Generation Surveillance System), vaccination records (from the National Immunisation Management Service), patient demographics, and cancer records from England, UK, from Dec 8, 2020, to Oct 15, 2021. Adults (aged ≥18 years) with cancer in the UKCCEP registry were identified via Public Health England's Rapid Cancer Registration Dataset between Jan 1, 2018, and April 30, 2021, and comprised the cancer cohort. We constructed a control population cohort from adults with PCR tests in the UKCCEP registry who were not contained within the Rapid Cancer Registration Dataset. The coprimary endpoints were overall vaccine effectiveness against breakthrough infections after the second dose (positive PCR COVID-19 test) and vaccine effectiveness against breakthrough infections at 3-6 months after the second dose in the cancer cohort and control population | ||
| 520 | |a FINDINGS: The cancer cohort comprised 377 194 individuals, of whom 42 882 had breakthrough SARS-CoV-2 infections. The control population consisted of 28 010 955 individuals, of whom 5 748 708 had SARS-CoV-2 breakthrough infections. Overall vaccine effectiveness was 69·8% (95% CI 69·8-69·9) in the control population and 65·5% (65·1-65·9) in the cancer cohort. Vaccine effectiveness at 3-6 months was lower in the cancer cohort (47·0%, 46·3-47·6) than in the control population (61·4%, 61·4-61·5) | ||
| 520 | |a INTERPRETATION: COVID-19 vaccination is effective for individuals with cancer, conferring varying levels of protection against breakthrough infections. However, vaccine effectiveness is lower in patients with cancer than in the general population. COVID-19 vaccination for patients with cancer should be used in conjunction with non-pharmacological strategies and community-based antiviral treatment programmes to reduce the risk that COVID-19 poses to patients with cancer | ||
| 520 | |a FUNDING: University of Oxford, University of Southampton, University of Birmingham, Department of Health and Social Care, and Blood Cancer UK | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Starkey, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Ionescu, Maria C |e verfasserin |4 aut | |
| 700 | 1 | |a Little, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Tilby, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Tripathy, Arvind R |e verfasserin |4 aut | |
| 700 | 1 | |a Mckenzie, Hayley S |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Hajji, Youssra |e verfasserin |4 aut | |
| 700 | 1 | |a Barnard, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Benny, Liza |e verfasserin |4 aut | |
| 700 | 1 | |a Burnett, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Cattell, Emma L |e verfasserin |4 aut | |
| 700 | 1 | |a Charman, Jackie |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, James J |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Ghafoor, Qamar |e verfasserin |4 aut | |
| 700 | 1 | |a Illsley, George |e verfasserin |4 aut | |
| 700 | 1 | |a Harper-Wynne, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Hattersley, Rosie J |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Alvin J X |e verfasserin |4 aut | |
| 700 | 1 | |a Leonard, Pauline C |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Justin K H |e verfasserin |4 aut | |
| 700 | 0 | |a NCRI Consumer Forum |e verfasserin |4 aut | |
| 700 | 1 | |a Pang, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Pascoe, Jennifer S |e verfasserin |4 aut | |
| 700 | 1 | |a Platt, James R |e verfasserin |4 aut | |
| 700 | 1 | |a Potter, Vanessa A |e verfasserin |4 aut | |
| 700 | 1 | |a Randle, Amelia |e verfasserin |4 aut | |
| 700 | 1 | |a Rigg, Anne S |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Tim M |e verfasserin |4 aut | |
| 700 | 1 | |a Roques, Tom W |e verfasserin |4 aut | |
| 700 | 1 | |a Roux, René L |e verfasserin |4 aut | |
| 700 | 1 | |a Rozmanowski, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Tuthill, Mark H |e verfasserin |4 aut | |
| 700 | 1 | |a Watts, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Iveson, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Siow Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Middleton, Gary |e verfasserin |4 aut | |
| 700 | 1 | |a Middleton, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Protheroe, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Fittall, Matthew W |e verfasserin |4 aut | |
| 700 | 1 | |a Fowler, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Kinloch, Emma |e investigator |4 oth | |
| 700 | 1 | |a Lam, Emily |e investigator |4 oth | |
| 700 | 1 | |a Murphy, Gillian |e investigator |4 oth | |
| 700 | 1 | |a Rhodes, Malcolm |e investigator |4 oth | |
| 700 | 1 | |a Robinson, Kate |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Oncology |d 2000 |g 23(2022), 6 vom: 26. Juni, Seite 748-757 |w (DE-627)NLM117859516 |x 1474-5488 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:6 |g day:26 |g month:06 |g pages:748-757 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1470-2045(22)00202-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 6 |b 26 |c 06 |h 748-757 | ||